Multimodal Artificial Intelligence in Cerebral Small Vessel Disease: From Risk Prediction to Personalised Management
Aging and Disease · 2026
DOI: 10.14336/ad.2026.1083 ↗Abstract
Cerebral small vessel disease (CSVD) is a major substrate for cerebrovascular and neurodegenerative conditions. However, its subtle and diffuse lesions hinder early detection and timely intervention. This clinically oriented review examines applications of artificial intelligence (AI) in CSVD, focusing on the integration of imaging with clinical, molecular or digital data. It covers three clinical areas: risk stratification and prognosis, diagnosis and quantitative assessment, and personalised management. We distinguish between findings in CSVD cohorts, evidence from other populations and proposed applications. We consider internal and external validation and evidence of clinical impact. Prediction models have been developed for CSVD screening and for estimating the risk of lesion progression, cognitive decline and vascular events. Selected studies have evaluated automated lesion quantification across multiple centres. Imaging and digital measures have also been used to assess current cognitive and gait impairment. AI-assisted treatment selection, remote monitoring and rehabilitation remain at an early stage, and their clinical benefits in CSVD have yet to be established. We discuss key requirements for clinical translation, including harmonised data acquisition, annotation aligned with neuroimaging standards, external validation and prospective evaluation of safety, equity and value in clinical practice. The review emphasises CSVD-specific phenotypes and longitudinal management, with outcomes extending beyond imaging to cognition, gait, affect and independence in activities of daily living. Future studies should establish whether these approaches improve clinical assessment and patient outcomes compared with current practice.
EUVIMED